3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Prostatic Neoplasms
14
Breast Neoplasms
12
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Stage II Prostate Adenocarcinoma
1
Skin Diseases
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Neoplasms
1
Metastatic Neuroendocrine Prostate Cancer
1
Inflammatory Breast Neoplasms
1
Dementia
1
Cognitive Dysfunction
1
Carcinoma, Ductal, Breast
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled